C

    Caris Life Sciences, Inc. Common Stock (CAI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.63
    -0.75 (-2.84%)

    Market Cap: $7.25B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(3/5)
    Avg Surprise
    -542.71%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.03
    Range$0.00 - $0.07
    9 analysts
    EPS Revisions
    2
    0
    7d
    2
    3
    30d
    EPS Estimate Drift
    90d ago$0.05+56.8%
    60d ago$0.04+47.3%
    30d ago$0.04+47.3%
    7d ago$0.04+36.1%
    Current$0.03
    Revenue Consensus
    $255M
    Range$243M - $263M
    11 analysts
    Dec 31, 2026
    EPS Consensus$0.12
    Range$0.03 - $0.24
    10 analysts
    Revenue Consensus
    $326M
    Range$302M - $332M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.12---
    Sep 26EST
    		-$0.03---
    Jun 26
    		$-0.54$-0.01-5300.00%Miss+51.4%
    Mar 26
    		$-0.00N/A+91.00%Beat+99.5%
    Dec 25
    		$0.28$0.01+2700.00%Beat-
    Sep 25
    		$0.08$-0.08+200.00%Beat-
    Jun 25
    		$-1.11$-0.22-404.55%Miss-
    Mar 25
    		$-0.35$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-140.98EV/EBITDA41.20x
    Price/FCF58.49xFCF Yield1.71%
    Profitability
    Profit Margin10.60%Operating Margin10.20%
    ROE20.10%ROIC13.29%
    Financial Health
    Debt/Equity0.66xInterest Coverage2.79x
    Current Ratio5.53xQuick Ratio4.88x
    Trading Statistics
    BetaN/AAvg Volume5.67M
    52-Week High$38.6852-Week Low$14.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.92
    SMA 20$22.68
    SMA 50$19.28
    SMA 200$20.93
    EMA 10$25.07
    EMA 20$23.15
    EMA 50$20.48
    EMA 200$21.21

    MACD

    Line: 2.34Signal: 2.03Hist: 0.31

    ADX

    ADX: 39.8+DI: 39.1-DI: 13.6

    Aroon & PSAR

    Aroon Up88.0
    Aroon DownN/A
    PSAR$28.32

    Bollinger Bands

    Upper Band$29.67
    Lower Band$15.69
    %B Position6164%(Upper)
    Band Width0.71

    RSI (14-Day)

    Neutral
    65.4

    Momentum Oscillators

    Stoch %K73.4
    Stoch %D83.0
    Williams %R-35.7
    ROC (10d)17.6%
    Momentum3.83
    CCI (20d)86.2
    MFI (14d)55.3

    Volatility Measures

    ATR (14d)$1.37(5.4%)
    StdDev (20d)3.49
    Hist Vol105.3%(High)

    Volume Flow

    VWAP$25.95
    OBV-18.5M
    AD Line-13.1M
    CMF (20d)0.178

    Volume Metrics

    Avg Vol (20d)5.8M
    Vol Ratio0.7x
    VWMA (20d)$22.82

    Pivot Points

    R3$28.08
    R2$27.73
    R1$27.06
    Pivot Point$26.71
    S1$26.03
    S2$25.68
    S3$25.01

    Advanced Oscillators

    TSI42.33
    Ultimate Osc59.4
    KST448.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Sep 2024Jun 2024Mar 2024Sep 2021Jun 2021Mar 2021
    Total Revenue$263.71M$216.17M$292.89M$216.83M$181.40M$120.92M$101.62M$100.05M$80.68M$100.83M$85.69M$80.80M
    Cost of Revenue$84.12M$74.83M$71.97M$69.33M$67.71M$63.85M$57.21M$62.49M$54.56M$46.74M$42.83M$42.21M
    Gross Profit$179.60M$141.35M$220.91M$147.51M$113.69M$57.06M$44.41M$37.55M$26.11M$54.09M$42.87M$38.59M
    Operating Expenses$152.67M$136.07M$132.50M$114.86M$131.67M$115.01M$105.25M$104.56M$118.34M$12.29M$10.17M$7.74M
    R&D$32.36M$31.32M$31.84M$21.62M$25.05M$23.07M$27.64M$24.79M$34.38M$0$0$0
    SG&A$66.55M$59.71M$56.51M$51.97M$64.37M$52.12M$40.85M$41.07M$45.47M$12.29M$10.17M$7.74M
    Operating Income$26.93M$5.28M$88.41M$32.64M$-17,989,000$-57,952,000$-60,842,000$-67,011,000$-92,225,000$66.44M$50.84M$48.76M
    Interest Income$6.82M$6.83M$7.01M$7.36M$1.62M$503,000$1.74M$2.64M$1.77M$0$0$0
    Interest Expense$9.23M$12.81M$11.36M$13.51M$19.21M$12.78M$13.80M$13.67M$9.29M$11.61M$11.11M$11.17M
    Income Before Tax$-614,000$-644,000$81.96M$24.32M$-71,790,000$-102,581,000$-67,729,000$-66,186,000$-111,028,000$54.83M$39.80M$37.18M
    Income Tax Expense$23,000$-134,000$0$0$0$0$0$0$0$3.68M$1.86M$2.50M
    Net Income$-637,000$-510,000$81.96M$24.32M$-71,790,000$-102,581,000$-67,729,000$-66,186,000$-111,028,000$51.16M$37.94M$35.74M
    EBITDA$8.63M$13.02M$97.60M$37.80M$-40,036,000$-81,312,000$-43,316,000$-55,152,000$-84,033,000$87.72M$80.39M$77.12M
    EBIT$1.79M$5.33M$93.31M$30.47M$-54,200,000$-90,302,000$-55,674,000$-55,152,000$-101,738,000$54.83M$50.91M$48.35M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CAI

    News

    Maxi Investments CY Ltd Makes New $3.75 Million Investment in Caris Life Sciences, Inc. $CAI

    Maxi Investments CY Ltd has made a new $3.75 million investment in Caris Life Sciences, Inc., purchasing 210,670 shares. This investment represents a 0.07% stake in the company. Caris Life Sciences also recently authorized a $100 million share buyback program, and analysts generally maintain a "Moderate Buy" consensus rating for the stock with an average price target of $26.33.

    MarketBeat•8/25/26•
    Bullish

    Caris Life Sciences (NASDAQ: CAI) trust plans another stock sale

    The GEORGE H POSTE REVOCABLE TRUST plans to sell 100,000 shares of Caris Life Sciences (CAI) common stock under Rule 144, with an aggregate market value of $2,606,320.00. These shares were acquired through previously exercised options, and the proposed sale date is August 11, 2025. This filing also discloses two prior sales by George Poste in August 2026, totaling 50,000 shares.

    Stock Titan•8/24/26•
    Neutral

    Mitsubishi UFJ Asset Management Co. Ltd. Invests $1.52 Million in Caris Life Sciences, Inc. $CAI

    Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake worth $1.52 million in Caris Life Sciences, Inc. by purchasing 85,600 shares during the second quarter. Several other institutional investors also increased or initiated smaller positions in the company. Caris Life Sciences, which specializes in molecular profiling and precision medicine for oncology, currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $26.33.

    MarketBeat•8/22/26•
    Somewhat-Bullish

    Caris Life Sciences (CAI) investors TSSP and Alan Waxman fall below 5% ownership

    TSSP Sub-Fund HoldCo, LLC and Alan Waxman have reported updated ownership positions in Caris Life Sciences, Inc. common stock, indicating they now hold less than 5% of the outstanding shares. As of June 30, 2026, their beneficial ownership stands at 2.4% and 2.6% respectively, triggering an exit reporting from five-percent-holder status. This change in ownership is based on 282,680,695 shares outstanding as of May 5, 2026.

    Stock Titan•8/7/26•
    Somewhat-Bearish

    Caris Life Sciences Inc. (CAI) Stock Price | Live Quotes & Charts | NASDAQ

    This page provides live quotes and charts for Caris Life Sciences Inc. (CAI) stock, showing its current price at $22.69, a gain of 13.45%. It also includes sections for analyst ratings and earnings information, although specific data for these sections is not currently available for CAI. The article is hosted on a financial education platform by Timothy Sykes, a self-made millionaire known for trading penny stocks.

    Timothy Sykes•8/7/26•
    Bullish

    Frequently Asked Questions About CAI

    Does CAI pay dividends?
    Caris Life Sciences, Inc. Common Stock (CAI) does not currently pay a regular dividend.
    What is CAI's market cap?
    Caris Life Sciences, Inc. Common Stock (CAI) has a market capitalization of $7.25B with a current stock price of $25.63.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In